Bauhinia variegata Linn. (Kanchnar)

Abstract

Bauhinia variegata Linn., commonly known as Kanchnar, Mountain Ebony, or Orchid Tree, is an important medicinal plant belonging to the family Fabaceae (Caesalpiniaceae). It has been extensively used in traditional systems of medicine such as Ayurveda, Unani, and folk medicine for the treatment of various diseases including thyroid disorders, diabetes mellitus, inflammatory conditions, skin diseases, gastrointestinal disorders, and cancer. Different parts of the plant such as bark, leaves, flowers, seeds, and roots possess significant therapeutic value.

Keywords

Introduction

Figure 3: Graphical Illustration of pharmacological activities of Bauhinia Spp. - Kachnar (BV, BP, BA, BB, BR, BT)[40]

Plate 1: Bark of Bauhinia variegata showing external and internal characteristics[5]

Fig.1: Flower and leave of BV showing characteristic pink flowers and bilobed leaves[1,40]

Plate 2: T.S of Bauhinia variegata stem bark (Abbreviations: Cx: cortex; Ph: phloem; Xy: xylem; MR: medullary rays)[5]

Pericycle[5,22]:

• Pericyclic fibers with narrow lumen, lignified, broad-walled, tapering ends[5,22]
• Bordered by sclerenchymatic cells[5,23]

Phloem[5,22]:

• Well-developed vascular bundle[5,22]
• Xylem (upper), Phloem (lower)[1,5]
• Contains: sieve tubes, companion cells, crystal fibers, phloem fibers, parenchyma, stone cells[23,40]
• Stone cells in radial rows and tangential bands[5,22]
• Crystal fibers (10–25 chambers) with calcium oxalate prisms[22,23,]

Medullary Rays:

• Uni- to biseriate rays traverse phloem[5,40]
• Stone cells present in rays[5,40]

Calcium Oxalate Crystals:

• Prismatically distributed[5,22,40]

Transverse Section of Leaf

Mesophyll:

• Palisade cells: 2–3 layers under upper epidermis[27,28]
• Spongy parenchyma above lower epidermis[27,28]

Midrib:

• Concave shape[27,28]
• Well-developed vascular bundle bordered by sclerenchymatic cells[27,28]
• Calcium oxalate crystals between epidermis[27,28]

Trichomes:

• Unicellular and multicellular uniseriate[29,40]
• Unicellular sessile[29,40]
• More common on lower epidermis[29,40]

5.3 Powder Characteristics

Microscopic examination of powdered bark reveals[5,30]:

• Cork cells: Polygonal, occasionally brownish[1,5]
• Fibers: Lignified, in groups of 3–5[30,40]
• Calcium oxalate crystals: In rows around fiber groups[5,30]
• Starch grains: Simple, 20–25 μm[30,40]
• Stone cells: Lignified walls[1,5]

5.4 Diagnostic Features

Key identification characteristics[1,5]:

• 10–20 layers of cork cells[1,5]
• Abundant lignified fibers and stone cells[1,5]
• Crystal fibers with calcium oxalate[1,5]
• Medullary rays in phloem[1,5]
• Starch grains, tannins[1,5]
• Presence of sterols, reducing sugars, glycosides[1,5]

6. PHYTOCHEMICAL PROFILE

B. variegata contains diverse bioactive phytochemicals contributing to its pharmacological activities [10,11].

6.1 Major Phytochemical Classes

1. Flavonoids[5,8]
2. Tannins[11,40]
3. Terpenoids[10,11]
4. Saponins[11,40]
5. Cardiac glycosides[10,11]
6. Alkaloids[11,13]
7. Phenolic compounds[13,14]
8. Steroids[10,11]
9. Amino acids[34,40]
10. Fixed oils and fatty acids[34,40]

6.2 Phytochemical Constituents by Plant Part

6.2.1 Leaves

Major compounds:

• Flavonoids: Quercetin, rutin, quercetrin, kaempferol-3-glucoside, apigenin, apigenin-7-O-glucoside[5,8]
• Long-chain compounds: Heptatriacontane-12,13-diol, dotetracont-15-en-9-ol[32,40]
• Terpenoids: Lupeol[20,40]
• Steroids: β-sitosterol[6,24]
• Others: Tannins, alkaloids, cardiac glycosides, vitamin C, reducing sugars[5,10]

Biological activities: Antifungal, antimicrobial, antidiabetic, hypoglycemic, anticancer[15,32]

6.2.2 Flowers

Major compounds:

• Anthocyanins: Cyanidin-3-glucoside, malvidin-3-glucoside, peonidin-3-glucoside[33,40]
• Flavonoids: Quercitroside, isoquercitroside, rutoside, taxifoline rhamnoside, kaempferol-3-glucoside[33,40]
• Acids: Ascorbic, aspartic, glutamic, octadecanoic acids[33,40]

Biological activities: Antidiarrheal, antidiabetic, antioxidant, antihyperlipidemic[3,35]

6.2.3 Seeds

Major compounds:

• The following are amino acids: proline, serine, threonine, tyrosine, valine, histidine, isoleucine, lysine, methionine, phenylalanine, aspartic, glutamic, arginine, glycine, alanine, and histidine. [34,40]
• Fatty acids: Oleic, linoleic, palmitic, stearic, myristic acids[34,40]
• Others: Proteins and carbohydrates[34,40]

Biological activities: Haemagglutinating properties[62,40]

6.2.4 Stem Bark

Major compounds:

• Steroids: Hentriacontane, octacosanol, β-sitosterol, stigmasterol[28,40]
• Flavonoids: 5,7-dihydroxyflavanone-4'-O-α-L-rhamnopyranosyl-β-D-glucopyranoside, lupeol, kaempferol-3-glucoside, naringenin-5,7-dimethyl ether[28,38]
• Phenanthrene: 2,7-dimethoxy-3-methyl-9,10-dihydrophenanthrene-1,4-dione (bauhinione)[38,40]

Biological activities: Antitumor, antiulcer, immunomodulatory, hepatoprotective, antibacterial [15,17]

6.3 Key Bioactive Markers

6.3.1 Quercetin

• Class: Flavonoid[5,32]
• Source: Leaves, flowers[5,8]
• Activities: Antioxidant, anti-inflammatory, anticancer, cardioprotective[24,40]
• Mechanism: Free radical scavenging, metal chelation, enzyme modulation[24,40]

6.3.2 β-Sitosterol

• Class: Phytosteroid[6,24]
• Source: Leaves, stem bark, seeds[6,24]
• Activities: Anticancer, antidiabetic, anti-inflammatory, immunomodulatory[6,40]
• Mechanism: Inhibits cholesterol absorption, modulates cell membrane fluidity[6,40]

6.3.3 Lupeol

• Class: Pentacyclic triterpenoid[20,40]
• Source: Leaves, stem bark[20,28]
• Activities: Anticancer, anti-inflammatory, antimicrobial, hepatoprotective[20,40]
• Mechanism: Induces apoptosis, inhibits NF-κB signaling[20,40]

6.3.4 Kaempferol

• Class: Flavonoid[5,40]
• Source: Leaves, flowers, stem bark[5,28]
• Activities: Antioxidant, anticancer, cardioprotective, neuroprotective[5,40]
• Mechanism: Free radical scavenging, signaling pathway modulation[5,40]

6.4 Extraction Methods

Leaves

• Method: Soxhlet extraction[1,40]
• Solvents: Petroleum ether (60–80°C), chloroform (50–60°C), ethanol (68–78°C), methanol, water[1,40]
• Yield: Petroleum ether (9.50% w/w), Chloroform (7.65%), Methanol (8.95%), Ethanol (8.50%), Water (0.30%)[40,41]

Flowers

• Defatting: Petroleum ether[42,40]
• Extraction: Hot percolation with 95% ethanol[42,40]
• Yield: 20.8% w/w[42,40]
• Fractionation: n-hexane, CH?Cl?, EtOAc, EtOH fractions[42,40]

Stem Bark

• Method: Percolation with 80% methanol[44,40]
• Concentration: Rotary vacuum evaporator[44,40]
• Column chromatography: Silica gel with hexane/ethyl acetate gradient[44,45]

7. PHARMACOLOGICAL ACTIVITIES

Extensive research has validated numerous pharmacological properties of B. variegata through in vitro and in vivo studies[12,13].

7.1 Antioxidant Activity

Mechanism:

• Free radical scavenging (DPPH, superoxide, nitric oxide, hydrogen peroxide)[19,67]
• Metal chelation[19,40]
• Lipid peroxidation inhibition[19,40]
• Enhancement of endogenous antioxidant enzymes (SOD, catalase, GPx)[19,40]

Active compounds: Quercetin, rutin, kaempferol, apigenin, phenolic acids, tannins[19,34,]

Evidence:

• Ethyl acetate, methanol, and aqueous extracts showed significant DPPH scavenging[67,69]
• Bark extracts demonstrated considerable activity in reducing power and free radical scavenging assays (p > 0.01, p < 0.001)[69,40]
• Dose-dependent activity comparable to standards (BHA, BHT, ascorbic acid, quercetin)[67,69]

Clinical significance: Prevention of oxidative stress-related diseases (diabetes, cardiovascular disorders, cancer, neurodegenerative diseases)[19,40]

7.2 Antidiabetic Activity

Mechanism:

• Enhancement of glucose metabolism[1,25]
• Improvement of insulin sensitivity[25,40]
• Reduction of hepatic glucose production[25,40]
• Protection of pancreatic β-cells[25,40]

Active compounds: Quercetin, kaempferol, glucokinin, terpenoids[25,26]

Evidence:

• STZ-induced diabetes: Ethanolic, aqueous, and hydro-alcoholic extracts (200–400 mg/kg) significantly reduced blood glucose in type I and II diabetes models[1,25]
• Alloxan-induced diabetes: Similar hypoglycemic effects[59,99]
• Flower extracts demonstrated antidiabetic properties[1,23]

Clinical relevance: Potential adjuvant therapy for diabetes management[25,26]

7.3 Anticancer and Antitumor Activity

Mechanism:

• Induction of apoptosis[15,17]
• Cell cycle arrest[15,17]
• Inhibition of angiogenesis[15,40]
• Modulation of signaling pathways (NF-κB, MAPK)[15,40]
• Enhancement of immune response[15,53,]

Active compounds: Quercetin, β-sitosterol, lupeol, flavonoids, lectins[14,15]

Evidence:

• Dalton's Ascitic Lymphoma: Ethanolic extract increased peritoneal cell count (macrophage activation, cytokine production)[53,90]
• Ehrlich Ascites Carcinoma: Cytotoxic activity in mice cell lines[90,40]
• DMBA and croton oil-induced skin carcinogenesis: Methanolic stem bark extract (500–1000 mg/kg) inhibited papilloma development, reduced tumor incidence and number, decreased tumor burden, restored glutathione levels[57,91]
• N-nitrosodiethylamine-induced liver tumors: Ethanolic stem extract showed chemoprevention[61,93]
• COLO 320 cell lines: Active fractions showed anticancer activity[23,40]
• 30-day studies: Increased life span, smaller tumors in micronucleus and chromosomal aberration tests[29,40]

Clinical relevance: Potential for anticancer agent development and adjuvant cancer therapy[15,30]

7.4 Anti-inflammatory Activity

Mechanism:

• Inhibition of COX and LOX[31,75]
• Suppression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)[31,75]
• Inhibition of NF-κB activation[31,40]
• Reduction of inflammatory mediators[31,40]

Active compounds: Kaempferol, quercetin, apigenin, triterpene caffeate, flavanol glycosides[31,36]

Evidence:

• Carrageenan-induced paw edema: Isolated flavanol glycoside showed significant anti-inflammatory activity[36,64]
• CFA-induced arthritis: Ethanolic extract (250 mg/kg) for 15 days reduced paw edema volume, decreased cholesterol, triglycerides, ALP, ALT, modulated antioxidant enzymes[51,82]
• LPS and IFN-γ induced cytokine production: Six flavonoids and one triterpene caffeate suppressed cytokine production[64,75]

Clinical relevance: Treatment of arthritis, IBD, inflammatory conditions[31,51]

7.5 Antimicrobial Activity

Mechanism:

• Disruption of bacterial cell membrane[18,60]
• Inhibition of protein synthesis[18,60]
• Interference with DNA replication[18,40]
• Antifungal activity via cell wall disruption[74,40]

Active compounds: Flavonoids, tannins, alkaloids, phenolic compounds[15,58] Evidence:

Antibacterial:

• Gram-positive: Bacillus subtilis (highly susceptible, 14 mm inhibition zone at 22 mg/mL), Staphylococcus aureus[58,70]
• Gram-negative: Salmonella typhi, E. coli, Enterobacter aerogenes, Klebsiella pneumoniae, Pseudomonas aeruginosa, Vibrio cholerae, Shigella dysenteriae[60,70]
• Ethanolic extracts more effective against gram-positive bacteria[70,73]
• Alcoholic leaf extract showed highest activity vs. petroleum ether and chloroform[72,40]

Antifungal:

• Methanolic leaf extracts inhibited Aspergillus fumigatus and Aspergillus niger[74,40]

Clinical relevance: Treatment of infections, potential for novel antimicrobial development[18,34]

7.6 Hepatoprotective Activity

Mechanism:

• Reduction of hepatic lipid peroxidation[7,54,]
• Enhancement of antioxidant defense[7,22]
• Restoration of liver enzyme levels[54,94]
• Protection against hepatotoxins[54,94]

Evidence:

• CCl?-induced hepatotoxicity: Ethanolic stem bark extract (100–200 mg/kg) significantly reduced AST, ALT, ALP, GGTP[7,54]
• DEN-induced liver tumors: Ethanolic stem extract showed chemoprevention, increased glutathione transferase, glutathione peroxidase[61,93,]

Clinical relevance: Liver disorder treatment, adjuvant in hepatotoxic drug therapy[7,22]

7.7 Nephroprotective Activity

Evidence:

• Gentamicin-induced nephrotoxicity: Ethanolic and aqueous root extracts (200–400 mg/kg) showed strong nephroprotective effect, reduced serum creatinine, serum urea, urine creatinine, BUN[77,78]
• Cisplatin-induced nephrotoxicity: Ethanolic whole stem extract (400 mg/kg) for 14 days decreased serum creatinine, serum urea, urine creatinine, albumin; weight gain, increased urine output, minimal histological damage[66,78]

7.8 Other Activities

8. QUALITY CONTROL AND STANDARDIZATION

Standardization ensures consistent quality, safety, and efficacy of herbal drugs[26,27].

8.1 Physicochemical Parameters

Ash Values

Interpretation[1,5]: High acid-insoluble ash indicates contamination;

8.2 Quantitative Phytochemical Analysis

Significance: High phenolic/flavonoid content correlates with antioxidant activity; mucilage supports GI applications[19,40]

8.3 Chromatographic Methods

Thin Layer Chromatography (TLC)

Petroleum Ether Extract:

• Solvent system: Petroleum ether:Ethyl acetate (95:5)[30,40]
• Detection: UV 254/366 nm, Cerric ammonium sulphate spray[30,40]
• Compounds detected: 4[30,40]

Chloroform Extract:

• Solvent system: Chloroform: Methanol (80:20)[30,40]
• Compounds detected: 3[30,40]

HPTLC

• Lupeol quantification: Densitometric HPTLC, violet bands at Rf 0.65[20,40]
• Fingerprint analysis: 11 peaks detected for B. variegata leaves[22,40]
• Application: Quality control, standardization[20,22]

8.4 Recommended Standardization Markers

Primary markers:

1. Quercetin (HPLC/HPTLC)[24,40]
2. Lupeol (HPTLC)[20,40]
3. β-sitosterol (GC-MS)[23,40]
4. Kaempferol (HPLC)[24,40]

Secondary markers:

1. Total flavonoid content[40]
2. Total phenolic content[19,40]
3. Total tannin content[20,40]

8.5 Dosage Forms and Recommended Doses

9. FORMULATIONS AND CLINICAL APPLICATIONS

9.1 Classical Ayurvedic Formulations

9.1.1 Kanchnar Guggul

Composition (12 ingredients):

• Bauhinia variegata stem bark (Kanchnar) – 480 g[7,11]
• Commiphora wightii oleo-resins purified (Guggulu-Shuddha) – 996 g[11,40]
• Terminalia chebula pericarp (Haritaki) – 96 g[7,40]
• Terminalia bellerica pericarp (Bibhitaka) – 96 g[7,40]
• Phyllanthus emblica pericarp (Amalaki) – 96 g[11,40]
• Zingiber officinale rhizome (Sunthi) – 48 g[7,11]
• Piper nigrum fruits (Marica) – 48 g[7,11]
• Piper longum fruits (Pippali) – 48 g[11,40]
• Crataeva nurvala stem bark (Varuna) – 48 g[7,11]
• Elettaria cardamomum seeds (Ela) – 12 g[7,40]
• Cinnamomum zeylanicum stem bark (Tvak) – 12 g[11,40]
• Cinnamomum tamala leaves (Tejpatra) – 12 g[7,11]

Properties:

• Kanchnar and Guggulu possess Deepan, Pachan, Vatta-Kaphashamak, Shoth-har, Lekhan, Bhedi properties[7,11]
• Guggulu oleo-resins have potent anti-inflammatory (shothhara) effect[11,40]

Indications:

• Gandamala (cervical lymphadenitis)[11,12]
• Apachi (chronic lymphadenopathy/scrofula)[7,40]
• Granthi (cyst)[7,40]
• Gulma (abdominal lump)[11,40]
• Vrana (ulcer)[7,11]
• Kustha (skin diseases)[7,40]
• Bhagandara (fistula-in-ano)[11,40]
• Slipada (filariasis)[7,11]
• Benign and malignant tumors[7,11]

Dosage: 2–4 tablets twice daily with warm water (as per physician's advice)[7,40]

Listed in: Indian Ayurvedic Pharmacopoeia, Ayurvedic Formulary[7,40]

9.1.2 Other Classical Formulations

1. Kanchan Gutika – Glandular swellings, tumors[36,40]
2. Gandamala Kundan Rasa – Goitre, cervical lymphadenitis[36,40]
3. Gulkand Kanchnar – Constipation, digestive disorders[36,40]
4. Kanchanaradi Kwatha – Thyroid disorders, glandular swellings[36,37]
5. Ushirasava – Heavy menstrual bleeding, skin diseases[37,40]
6. Chandanasava – Cardiac and digestive tonic[37,40]
7. Vidangarishta – Worm infestations, digestive disorders[37,40]

9.2 Clinical Applications

9.2.1 Thyroid Disorders

• Traditional use: Gandamala nashaka (thyroid problems), goitre[2,12]
• Clinical evidence: Experimental anti-goitrogenic activity; Kanchnar Guggul widely prescribed for hypothyroidism[87,88]

9.2.2 Cervical Lymphadenitis

• Traditional use: Gandamala (cervical lymphadenitis/scrofula)[2,12]
• Clinical evidence: Increases efficacy of anti-tubercular medications; anti-inflammatory and immunomodulatory effects[86,40]

9.2.3 Diabetes Mellitus

• Traditional use: Antidiabetic in traditional texts[25,26]
• Clinical evidence: Multiple animal studies demonstrate hypoglycemic effects; human trials needed[1,25]

9.2.4 Skin Diseases

• Traditional use: Kushtaghna (skin diseases), leprosy, discoloration[9,12]
• Clinical evidence: Antimicrobial, anti-inflammatory, wound healing documented[18,72]

9.2.5 Gastrointestinal Disorders

• Traditional use: Diarrhea, dysentery, ulcers[2,9]
• Clinical evidence: Antiulcer, antidiarrheal effects in animal models[56,80]

9.2.6 Cancer

• Emerging application: Several studies demonstrate anticancer potential; Kanchnar Guggul used as adjuvant therapy[15,30]
• Status: Requires extensive clinical validation[15,30]

9.3 Traditional Preparation Methods

Bark Decoction (Kwatha)

1. Take 10–20 g dried bark powder[38,40]
2. Add 8 parts water (80–160 mL)[38,40]
3. Boil until reduced to 1/4 volume[38,40]
4. Filter and consume warm[38,40]

Bark Paste

1. Take dried bark powder[6,7,40]
2. Mix with water, honey, or ghee to form paste[6,7,40]
3. Apply externally to wounds, ulcers, swellings[6,7,40]

9.4 Dosage and Administration

General guidelines:

• Powder: 3–6 g daily with water or honey[38,40]
• Decoction: 40–80 mL twice daily[38,40]
• Juice: 10–20 mL twice daily[38,40]
• Tablets (Kanchnar Guggul): 2–4 tablets twice daily with warm water[7,40]

Duration: Typically 1–3 months or as directed[40]

Precautions:

• Take under medical supervision[40]
• Inform healthcare provider about concurrent medications[40]
• Monitor for adverse effects[40]

10. RESEARCH GAPS AND FUTURE DIRECTIONS

Despite extensive traditional use and growing scientific evidence, several research gaps remain[1,40].

10.1 Phytochemistry

Current status: Many compounds identified; structures elucidated[13,14]

Gaps:

• Complete phytochemical profiling using metabolomics[1,40]
• Minor bioactive compound identification[1,40]
• Structure-activity relationship studies[1,40]
• Bioavailability and pharmacokinetic studies[1,40]

Future directions:

• Comprehensive metabolomic analysis[1,40]
• Novel compound isolation[1,40]
• Synergistic effects of compound mixtures[1,40]
• Standardized extracts with defined composition[1,40]

10.2 Pharmacology

Current status: Numerous in vitro/in vivo studies; mechanisms partially understood[12,13]

Gaps:

• Detailed mechanism of action for many effects[1,40]
• Dose-response relationships[1,40]
• Long-term efficacy studies[1,40]
• Comparative studies with standard drugs[1,40]
• Bioavailability and pharmacokinetics[1,40]

Future directions:

• Molecular-level mechanistic studies[1,40]
• Molecular target identification[1,40]
• Genomic and proteomic studies[1,40]
• Animal models mimicking human conditions[1,40]
• Combination therapy investigation[1,40]

10.3 Clinical Studies

Current status: Traditional use documented; animal studies supportive; limited human trials[1,40]

Gaps:

• Lack of randomized controlled trials (RCTs)[1,40]
• No Phase I, II, III clinical trials for most indications[1,40]
• Human safety and efficacy data lacking[1,40]
• Optimal dosage regimens not established[1,40]
• Long-term safety data absent[1,40]

Future directions:

• Well-designed RCTs for key indications (diabetes, thyroid disorders, cancer adjuvant, inflammation)[1,40]
• Phase I safety studies in healthy volunteers[1,40]
• Dose-finding studies[1,40]
• Long-term follow-up studies[1,40]
• Post-marketing surveillance[1,40]
• Pharmacovigilance systems[1,40]

10.4 Standardization and Quality Control

Current status: Some parameters established; TLC/HPTLC methods developed[20,22]

Gaps:

• Lack of universally accepted protocols[1,40]
• Validated biomarkers needed[1,40]
• Batch-to-batch variability not characterized[1,40]
• Geographical/seasonal variation influence unclear[1,40]

Future directions:

• Validated analytical methods (HPLC, GC-MS, LC-MS)[1,23]
• Reference standards for major compounds[1,40]
• DNA barcoding for authentication[1,40]
• Good Agricultural and Collection Practices (GACP)[1,40]
• Pharmacopeial monograph development [1,26]
• Quality by Design (QbD) approaches[1,40]

10.5 Toxicology

Current status: Generally considered safe; limited acute toxicity data[1,40]

Gaps:

• Comprehensive toxicity studies lacking (sub-acute, chronic, reproductive, genotoxicity, carcinogenicity)[1,40]
• Drug interaction studies[1,40]
• Safety in special populations (pregnant, children, elderly)[1,40]

Future directions:

• Systematic toxicity studies (OECD guidelines)[1,40]
• Drug-drug and drug-herb interaction studies[1,40]
• Toxicokinetic studies[1,40]
• Vulnerable population safety studies[1,40]
• Post-marketing adverse event monitoring[1,40]

10.6 Formulation Development

Current status: Traditional formulations established; some modern products available[7,11]

Gaps:

• Extraction method optimization[1,40]
• Novel drug delivery systems unexplored [1,40]
• Bioavailability enhancement strategies needed [1,40]
• Formulation stability studies lacking[1,40]

Future directions:

• Standardized extract development[1,40]
• Novel delivery systems (nanoparticles, liposomes, phytosomes, sustained-release) [1,40]
• Bioavailability enhancement (bioenhancers, self-emulsifying systems)[1,40]
• Stability studies and shelf-life determination [1,40]

10.7 Other Research Needs

Agricultural and conservation:

• Sustainable harvesting practices[1,40]
• Cultivation optimization[21,22,40]
• GACP implementation[1,40]
• Conservation strategies[1,40]

Regulatory aspects:

• Comprehensive monographs[1,40]
• International standard harmonization[1,40]
• Evidence for regulatory approvals[1,40]
• Intellectual property protection[1,40]

Integration with modern medicine:

• Evidence-based integrative guidelines[1,40]
• Healthcare provider education[1,40]
• Drug interaction studies[1,40]
• Adjuvant use protocols[1,40]

REFERENCES

1. Abdel-Halim AH, Fyiad AAA, Aboulthana WM, El-Sammad NM, Youssef AM, Ali MM. Assessment of the anti-diabetic effect of Bauhinia variegata gold nano-extract against streptozotocin induced diabetes mellitus in rats. J. Applied Pharm. Sci. 2020;10(05):077–091.
2. Agnivesha. Charaka Samhita. Commentary by Pt. Kashinatha Shastri and Dr. Gangasahaya Pandeya, Part 1. Varanasi: Chaukhamba Sanskrit Sansthan; Reprint 2006.
3. Anonymous. The Wealth of India: A Dictionary of Indian Raw Materials and Industrial Products- Raw Materials. Publication and Information Directorate, CSIR, New Delhi, India. 1988;Vol.2:B:56.
4. Anonymous. Useful Tropical plants - Bauhinia variegata L. 2024. Available from: https://tropical.theferns.info/viewtropical.php?id=Bauhinia+variegata
5. Arora SK, Hussain M, Subhash RY, Moharir K, Pande V, Ittadwar A. Bauhinia purpurea: An Updated Pharmacological Profile. Journal of Ayurvedic and Herbal Medicine. 2020;6(2):81-85.
6. Babu S, Jayaraman S. An update on β-sitosterol: A potential herbal nutraceutical for diabetic management. Biomed Pharmacother. 2020;131:110702.
7. Bodakhe SH, Ram A. Hepatoprotective properties of Bauhinia variegata bark extract. Yakugaku zasshi. 2007 Sep 1;127(9):1503-7.
8. Brain KR, Turner T. The Practical Evaluation of Phytopharmaceuticals. Wright-Scientechnica, Bristol. 1975:10-12.
9. Brummitt RK, Chikuni AC, Lock JM, Polhill RM. Leguminosae Subfamily Caesalpinioideae. Journal of Flora Zambesiaca. 2007;3(2):19-20.
10. Burrows JE, Burrows SM, Lötter MC, Schmidt E. Trees and Shrubs Mozambique. Publishing Print Matters (Pty), Cape Town. 2018:240.
11. Cechinel FV. Chemical composition and biological potential of plants from the genus Bauhinia. Phytother Res. 2009 Oct;23(10):1347-54.
12. Chandra TR, Suresh C, Sanghamitra D, Kumar GR. Kanchnara (Bauhinia variegata linn): a critical review. Int J Ayurveda Pharm Res. 2015;3(7):39-46.
13. Chauhan NS. Medicinal and aromatic plants of Himachal Pradesh. Indus publishing; 1999.
14. Chen VT, Tham M Vo, Phong T Bui, Duc NP Duong, Lam XN Duong, Diep Q Dinh, Hien TT Nguyen. Phytochemical Screening, Antioxidant Activity and α?Glucosidase Inhibitability of Bauhinia blakeana Dunn Leaf and Flower Extracts from Vietnam. Tropical Journal of Natural Product Research. 2023;7(4):2737-2743.
15. Dhale DA. Phytochemical screening and antimicrobial activity of Bauhinia variegata Linn. Journal of Ecobiotechnology. 2011 Oct 8;3(9).
16. Dhonde SM, Siraskar BD, Kulkarni AV, Kulkarni AS, Bingi SS. Haematinic activity of ethanolic extract of stem bark of Bauhinia variegata Linn. Int J Green Pharm. 2007;1(3-4):28-33.
17. dos Santos KM, Gomes IN, Oliveira RJ, Pinto FE, Oliveira B, Batista FP, et al. ID7 Isolated from Bauhinia variegata Stem Inhibits Tumor Progression and Metastatic Mechanisms of Triple Negative Breast Cancer in Vivo. Journal of Pharmacy and Pharmacology. 2019;7:368-84.
18. Dugasani S, Balijepalli MK, Tandra S, Pichika MR. Antimicrobial activity of Bauhinia tomentosa and Bauhinia vahlii roots. Pharmacognosy magazine. 2010 Jul;6(23):204.
19. Ghaisas MM, Shaikh SA, Deshpande AD. Evaluation of the immunomodulatory activity of ethanolic extract of the stem bark of Bauhinia variegata Linn. International Journal of Green Pharmacy (IJGP). 2009;3(1).
20. Golwala DK, Vaidya SK, Dholwani KK, Patel DS, Sahoo S. Antioxidant and antimutagenic (anticlastogenic) activity of alcoholic extract of Bauhinia variegata (Linn.) root. Eur. J. Med. Plants. 2020:32-39.
21. Gudavalli D, Pandey K, Gopal EDEV, Sable D, Ashwini S, Ghagare, Kate AS. Phytochemistry and pharmacological activities of five species of Bauhinia genus: A review. Journal of Fitoterapia. 2024;105830.
22. Gupta M, Mazumder UK, Siva Kumar T, Gomathi P, Sambath Kumar R. Antioxidant and hepatoprotective effects of Bauhinia racemosa against paracetamol and carbon tetrachloride induced liver damage in rats. Iran Journal of Pharmacol Ther. 2004;3(1):12-20.
23. Gupta N, Kondalkar SA, Arya M, Bharthi V, Paul B, Kondalkar A, Meena AK. Pharmacognostical, phytochemical, HPTLC and ethano-botanical study of Bauhinia purpurea L. pod. International Journal Pharmaceutical Science and Research. 2024;15(3):889-899.
24. Habib MR, Nikkon F, Rahman M, Haque ME, Karim MR. Isolation of stigmasterol and beta-sitosterol from methanolic extract of root bark of Calotropis gigantea (Linn). Pakistan journal of biological sciences: PJBS. 2007 Nov 1;10(22):4174-6.
25. Harborne JB. Phytochemical methods. 3rd eds. Chapman and Hall. New York. 1998:90,203.
26. Indian Pharmacopoeia. Government of India, Ministry of Health and Family Welfare. Delhi: Controller of Publications. 1996;2(35):448.
27. Kannan N, Renitta RE, Guruvayoorappan C. Bauhinia tomentosa stimulates the immune system and scavenges free radical generation in vitro. Journal of Basic Clin Physiol Pharmacol. 2010;21(2):157–68.
28. Kansal M, Shukla P, Shukla P. A Boon to Human Health-Bauhinia Variegata. Int J Pharmacogn. 2020;7:155-61.
29. Khanduri VP, Sharma CM. Pollen production in relation to pollination behaviour in some multipurpose Himalayan trees. Journal of Tropical Forest Science. 2001 Apr 1;13(2):394-6.
30. Khandelwal K. Practical pharmacognosy. Pragati Books Pvt. Ltd.; 2008 Sep 7.
31. Kirtikar KR, Basu BD. Indian Medicinal Plants. International Book Publisher, Dehradun. 1993.
32. Kirtikar KR, Basu BD. Indian medicinal plants. Basu, Bhuwane?wari Â?rama; 1918.
33. Kokoski J, Kokoski R, Salma FJ. Fluorescence of powdered vegetable drugs under ultraviolet radiation. J Am Pharm Ass. 1958;47:715-717.
34. Kumar A, Anand V, Dubey RC, Goel KK. Evaluation of antioxidant potential of alcoholic stem bark extracts of Bauhinia variegata Linn. J. Applied. Nat. Sci. 2019;11(1):235-239.
35. Kumar R, Gupta YK, Singh S, Arunraja S. Cissus quadrangularis attenuates the adjuvant induced arthritis by down regulating pro-inflammatory cytokine and inhibiting angiogenesis. Journal of ethnopharmacology. 2015 Dec 4;175:346-55.
36. Kumar S, Kumar R, Gupta YK, Singh S. In vivo anti-arthritic activity of Bauhinia purpurea Linn. Bark Extract. Indian journal of pharmacology. 2019 Jan 1;51(1):25-30.
37. Kumar V, Rathore K, Jain P, Ahmed Z. Biological activity of Bauhinia racemosa against diabetes and interlinked disorders like obesity and hyperlipidemia. Clin. Phytosci. 2017;3(1):7.
38. Lau CPY, Ramsden L, Saunders RMK. Hybrid origin of "Bauhinia blakeana" (Leguminosae: Caesalpinioideae), inferred using morphological, reproductive, and molecular data. American Journal of Botany. 2005;92(3):525–33.
39. Liu M, Dong J, Lin Z, Niu Y, Zhang X, Jiang H, Guo N, Li W, Wang H, Chen S. Rapid Screening Of Transferrin-Binders In The Flowers Of Bauhinia Blakeana Dunn By On-Line High-Performance Liquid Chromatography. Journal Of Chromatography A. 2016;1450:17-28.
40. Llamas KA. A Guide to Identification and Cultivation. Tropical flowering plants. 2003.